echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Annual Inventory 2021 Summary of Progress in Diffuse Large B-Cell Lymphoma

    Annual Inventory 2021 Summary of Progress in Diffuse Large B-Cell Lymphoma

    • Last Update: 2022-03-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Looking back on the past, looking forward to the future
    .

    On the occasion of the arrival of 2022, Yimaitong Hematology launched the "Annual Inventory" series of articles, summarizing the research fronts worthy of attention in the field of blood diseases in 2021
    .

    Today, we bring you a summary of "Diffuse Large B-Cell Lymphoma (DLBCL)", click on the title of the article to read the original text
    .

    01 Interview with a CSCO Expert: 1.
    2021 CSCO Expert Interview|Professor Zhu Jun: lonca shows preliminary efficacy, and the application prospect of R/R DLBCL new drug is worth looking forward to 2.
    2021 CSCO Expert Interview|Professor Cai Qingqing talks about the treatment of diffuse large B-cell lymphoma Progress 3.
    Professor Jin JieDLBCL has entered a new era of precision therapy, and CAR-T therapy brings new hopeProfessor Liu Hui: Stratified treatment strategies guided by DLBCL assessment tools | China Hematology Development Conference 3.
    Prof.
    Yu Wenjuan: Progress in the diagnosis and treatment of debilitated diffuse large B-cell lymphoma in the elderly2021 Jinling Lymphoma Forum 4.
    Prof.
    Cao Junning: Clinical features and treatment progress of EBV-positive DLBCLThe 6th Anti-Leukemia ·Lymphoma International Summit Forum 5.
    Prof.
    Zhao Donglu: Application Progress of Novel Antibodies in Diffuse Large B-Cell Lymphoma | 2021 Leukemia and Lymphoma Summit Forum 6.
    2021 CSCOProfessor Bai Ou: DLBCL Prognosis Exploration and Treatment Optimization 7 .
    Professor Zhou Hui: Standardized or individualized first-line treatment of DLBCL? | CSCO Anti-Lymphoma Alliance Tour Lecture 8.
    Prof.
    Liu Wei: The role of transplantation in DLBCL in the era of CAR-T therapy | CSCO Anti-Lymphoma Alliance Tour Lecture 9.
    What are the differences in the treatment and prognosis of DLBCL at different primary sites? Come and listen to what Professor Song Yuqin has to say about the interpretation of 03 big coffee: 1.
    2021 EHA first report | Zanubrutinib + Lenalidomide + R-CHOP in the treatment of DLBCL 2.
    2021 ASH Express | Li Jianyong, Zhu Huayuan: Zanubrutinib, Efficacy evaluation of lenalidomide + R-CHOP in the first-line treatment of newly diagnosed DLBCL 3.
    2021 ASH first look | Prof.
    Xu Wei interprets the application of anti-CD19 ADC in R/R DLBCL 4.
    2021 ASH | Prof.
    Qian Wenbin's team: Phase Ib study of novel CAR-T combined with tislelizumab in the treatment of relapsed/refractory DLBCL Demonstrated comprehensive evidence-based evidence in 6.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.